Clinical Trials · NCT06640972

Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

Name: Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Tirzepatide Semaglutide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Response Pharmaceuticals
Enrollment: 68
Start date: Sep 2024
Locations: 1 site, United States
Primary endpoint: Incremental Postprandial Triglycerides (TG)

View Tirzepatide compound reference